Inhibition of HIV-1 by Fusion Inhibitors
Keywords: BMS-378806; Cyclic depsipeptides; DNA strand elongation; Enfuvirtide; Fusion Inhibitors; Fuzeon; Gag-Pol precursor; HIV; HIV-1; HXB2 isolate; Highly Active Antiretroviral Therapy (HAART); Maraviroc; N126K; PRO542; S138A; Saquinavir; Siliquaria spongia mirabilis; T20; TORO phase III study; VIRIP; abacavir; acquired immunodeficiency syndrome; antiviral peptide; coronaviridae; didanosine; enfuvirtide; envelope glycoprotein complex; fusion inhibitors; gp120; gp41; guanine; human immunodeficiency virus type 1; immunoglobulin; indinavir; integrase; non-nucleoside RT inhibitors; nucleoside analogue; resistance; reverse transcriptase (RT); ritonavir; stavudine; thymidine; vicriviroc; viral Gag; virus entry; zidovudine
Document Type: Research Article
Publication date: November 1, 2010
- Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites